Literature DB >> 2843085

Daptomycin (LY146032) treatment of experimental enterococcal endocarditis.

L M Bush1, J A Boscia, D Kaye.   

Abstract

This study compared daptomycin (LY146032) with penicillin G procaine and vancomycin without and with gentamicin for treatment of experimental enterococcal endocarditis. The strain of Streptococcus (Enterococcus) faecalis used in this study was killed by daptomycin in vitro in broth but not in serum. In rabbits treated for 3 days, daptomycin significantly reduced bacterial counts of vegetations compared with no therapy but was significantly less effective than penicillin G procaine or vancomycin. Daptomycin-gentamicin significantly reduced bacterial counts of vegetations compared with daptomycin alone but was significantly less effective than vancomycin plus gentamicin. The efficacy of daptomycin-gentamicin did not differ significantly from that of penicillin G procaine-gentamicin. The lack of enterococcal killing by daptomycin alone in serum and in experimental endocarditis is probably related to the high protein binding of the agent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843085      PMCID: PMC172299          DOI: 10.1128/AAC.32.6.877

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Activity of LY146032 against Enterococci with and without high-level aminoglycoside resistance, including two penicillinase-producing strains.

Authors:  A R Wanger; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

2.  Comparison of broth and human serum as the diluent in the serum bactericidal test.

Authors:  F D Pien; R D Williams; K L Vosti
Journal:  Antimicrob Agents Chemother       Date:  1975-01       Impact factor: 5.191

3.  In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

4.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; S Willey; E Reiszner; P G Spitzer; G Caputo; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

5.  Comparison of two beta-lactamase-producing strains of Streptococcus faecalis.

Authors:  B E Murray; D A Church; A Wanger; K Zscheck; M E Levison; M J Ingerman; E Abrutyn; B Mederski-Samoraj
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

6.  Prevalence of high-level resistance to aminoglycosides in clinical isolates of enterococci.

Authors:  R C Moellering; C Wennersten; T Medrek; A N Weinberg
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

7.  Antibiotic synergism in enterococcal endocarditis.

Authors:  J Carrizosa; D Kaye
Journal:  J Lab Clin Med       Date:  1976-07

8.  Effect of protein binding on antibiotic activity in vivo.

Authors:  D J Merrikin; J Briant; G N Rolinson
Journal:  J Antimicrob Chemother       Date:  1983-03       Impact factor: 5.790

9.  High-level resistance to gentamicin in clinical isolates of enterococci.

Authors:  B D Mederski-Samoraj; B E Murray
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

10.  Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci.

Authors:  C Watanakunakorn; C Bakie
Journal:  Antimicrob Agents Chemother       Date:  1973-08       Impact factor: 5.191

View more
  27 in total

Review 1.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 2.  Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.

Authors:  Sebastiano Leone; Silvana Noviello; Silvano Esposito
Journal:  Infection       Date:  2015-09-01       Impact factor: 3.553

3.  Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model.

Authors:  E Bingen; C Doit; N Lambert-Zechovsky; M Tod; O Petitjean; F Bourgeois; P Mariani-Kurkdjian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

Review 4.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

5.  Effect of protein binding of daptomycin on MIC and antibacterial activity.

Authors:  B L Lee; M Sachdeva; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

6.  In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains.

Authors:  L M Bush; J A Boscia; M Wendeler; P G Pitsakis; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

7.  Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits.

Authors:  S Kennedy; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model.

Authors:  J I Blenkharn; J H Darrell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

9.  Antimicrobial susceptibility and molecular epidemiology of beta-lactamase-producing, aminoglycoside-resistant isolates of Enterococcus faecalis.

Authors:  S M Markowitz; V D Wells; D S Williams; C G Stuart; P E Coudron; E S Wong
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

10.  Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium.

Authors:  F Caron; M D Kitzis; L Gutmann; A C Cremieux; B Maziere; J M Vallois; A Saleh-Mghir; J F Lemeland; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.